CRYSTALLINE FORMS OF NLRP3 INFLAMMASOME INHIBITORS, CHEMICAL PROCESSES AND CHEMICAL COMPOUNDS

The specification generally relates to crystalline forms of inhibitors of the NLRP3 inflammasome, pharmaceutical compositions comprising such crystalline forms, chemical processes useful for the preparation of inhibitors of the NLRP3 inflammasome, and intermediate compounds useful in such processes....

Full description

Saved in:
Bibliographic Details
Main Authors PITHANI, Venkata Subhash, KARLSSON, Staffan, FUCHIGAMI, Ryuichi, LEUSER, Helena Bernadette
Format Patent
LanguageEnglish
French
Published 04.07.2024
Subjects
ACYCLIC OR CARBOCYCLIC COMPOUNDS
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The specification generally relates to crystalline forms of inhibitors of the NLRP3 inflammasome, pharmaceutical compositions comprising such crystalline forms, chemical processes useful for the preparation of inhibitors of the NLRP3 inflammasome, and intermediate compounds useful in such processes. Such crystalline forms and pharmaceutical compositions are useful in inhibiting NLRP3 inflammasome activity and may be useful as therapeutic agents. L'invention concerne de manière générale des formes cristallines d'inhibiteurs de l'inflammasome NLRP3, des compositions pharmaceutiques comprenant de telles formes cristallines, des processus chimiques utiles pour la préparation d'inhibiteurs de l'inflammasome NLRP3, ainsi que des composés intermédiaires utiles dans de tels processus. De telles formes cristallines et compositions pharmaceutiques sont utiles pour inhiber l'activité de l'inflammasome NLRP3 et peuvent être utiles en tant qu'agents thérapeutiques.
Bibliography:Application Number: WO2023EP87813